Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 19/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 12/20 | 1.00 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.68 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.68 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31125355 | 0.93 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| Vidofludimus SCHEMBL29869156 | 0.89 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL29868321 | 0.89 | DHODH (1.00) | DHODHNR4A2 | |
| SCHEMBL29868737 | 0.88 | DHODH (1.00) | DHODHNR4A2 | |
| SCHEMBL31026699 | 0.87 | DHODH (0.81) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| Vidofludimus SCHEMBL29868416 | 0.87 | DHODH (0.85) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL31326982 | 0.86 | DHODH (0.81) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL502818 | 0.85 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL249081 | 0.84 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL31244586 | 0.84 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032527-A1 | MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS | IMMUNIC AG (DE) | 2025-01-30 | — | — | US | disclosed |
| EP-4426315-A1 | MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS | Immunic AG (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-118382610-A | DHODH inhibitors containing carboxylic acid bioisosteres | 埃慕尼克股份公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-4320100-A1 | DEUTERATED DHODH INHIBITORS | Immunic AG (DE) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023073239-A1 | MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS | IMMUNIC AG (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022214691-A1 | DEUTERATED DHODH INHIBITORS | IMMUNIC AG (DE) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032527-A1 | MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS | SLC5A7, HCRTR1, SPHK1 | DHODH 717/4885NR4A2 2354/4885JMJD7 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.